Cosentyx Drug Market: Market Size & Forecast 2026

Cosentyx (generic: secukinumab) is a monoclonal antibody biologic drug developed and marketed by Novartis that targets interleukin-17A (IL-17A), a key protein involved in inflammatory and autoimmune responses. Approved for multiple conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, the drug is administered via subcutaneous injection and has become a cornerstone therapy in the dermatology and rheumatology spaces. The global market reached approximately $6.2 billion in 2025, with consistent expansion driven by broad therapeutic adoption and increasing physician preference for IL-17 inhibitor class therapies.

• •Primary indication remains plaque psoriasis, the largest revenue segment within the overall Cosentyx market
• •Drug is available via subcutaneous injection route, with ongoing interest in alternative administration formats
• •Market valuation of ~$6.2 billion in 2025 reflects established commercial presence across major pharmaceutical markets worldwide

The Cosentyx market benefits from rising global prevalence of autoimmune and inflammatory skin and joint conditions, with psoriasis affecting over 125 million people worldwide according to public health estimates. Expansion of approved indications beyond dermatology into rheumatology has significantly broadened the addressable patient population, while the drug's favorable efficacy and safety profile compared to earlier biologic therapies has strengthened prescribing patterns. Additionally, increasing healthcare access in emerging markets and growing insurance coverage for high-cost biologics are facilitating market expansion.

• •Growing prevalence of plaque psoriasis and psoriatic arthritis globally, particularly in developed nations with aging populations
• •Expanded label approvals across multiple autoimmune indications driving broader physician adoption
• •Biosimilar competition is still limited, allowing Novartis to maintain pricing power in near term

The market is segmented primarily by indication, plaque psoriasis (dominant segment), psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and other emerging indications. Distribution channels are split between hospital pharmacies, retail pharmacies, and specialty clinics. Geographically, North America represents the largest market due to favorable reimbursement policies and high biologics adoption, followed by Europe with strong market penetration, while Asia-Pacific is the fastest-growing region driven by improving healthcare infrastructure and rising disease awareness.

• •Plaque psoriasis accounts for the largest share of revenue within the indication-based segmentation
• •North America leads regional share, supported by comprehensive insurance coverage and high prescription rates
• •Asia-Pacific is projected as the fastest-growing regional segment through 2030 due to expanding market access

What are the recent trends and outlook?

The Cosentyx market is positioned for steady growth through 2030, supported by pipeline investigations into additional indications and combination therapy approaches. Biosimilar entry is expected to intensify around the mid-2020s as key patents expire, which will likely exert downward pressure on pricing but expand total addressable market through volume growth. Technological improvements in formulation and delivery, along with potential pediatric label expansions, represent near-term catalysts that could sustain above-market growth even as competitive pressures mount.

• •Projected market trajectory of ~8.5% CAGR through 2030 suggests continued expansion despite future biosimilar competition
• •Patent expiration timelines will trigger biosimilar launches in key markets, shifting competitive dynamics around mid-decade
• •Pipeline potential in additional indications and pediatric populations offers upside beyond current approved uses